Original ArticleDouble-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
Under an Elsevier user license
open archive
Key Words
AT-101
Bcl-2
Non-small cell lung cancer
Docetaxel
Apoptosis
Cited by (0)
Disclosure: Jon Holmlund, Brian Wood, and Lance Leopold are employed by Ascenta and have a proprietary interest in the company. The other authors declare no conflicts of interest.
Copyright © 2011 International Association for the Study of Lung Cancer. All rights reserved.